$4.60
arrow_drop_up5.02%Key Stats | |
---|---|
Open | $4.36 |
Prev. Close | $4.38 |
EPS | -1.94 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $430.67M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 4.30 | 4.55 |
52 Week Range | 3.36 | 11.23 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.94 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Thyroid Eye Disease Market to Accelerate Substantially by 2034, Assesses DelveInsight | Key Companies Developing ... - GlobeNewswire
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications